Endothelial ERK signaling controls lymphatic fate specification

Journal of Clinical Investigation

Volumn 123, Issue 3, 2013, Pages 1202-1215

  Deng, Yong ^a   Atri, Deepak ^a   Eichmann, Anne ^a,b   Simons, Michael ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b l'alimentation et l'Environnement   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIAMINO 1,4 BIS(2 AMINOPHENYLTHIO) 2,3 DICYANOBUTADIENE; 2 MORPHOLINO 8 PHENYLCHROMONE; CHICKEN OVALBUMIN UPSTREAM PROMOTER TRANSCRIPTION FACTOR 2; CONNEXIN 40; MITOGEN ACTIVATED PROTEIN KINASE; MUTANT PROTEIN; NEUROPILIN 1; PROTEIN KINASE B; RAF PROTEIN; SMOOTH MUSCLE ACTIN; TRANSCRIPTION FACTOR SOX18; VASCULOTROPIN A; VASCULOTROPIN C; VASCULOTROPIN RECEPTOR 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAROTID ARTERY; CONTROLLED STUDY; EMBRYO; EMBRYO DEVELOPMENT; ENDOTHELIUM CELL; ENZYME ACTIVATION; GAIN OF FUNCTION MUTATION; HUMAN; HUMAN CELL; LYMPH VESSEL; LYMPHANGIECTASIS; LYMPHANGIOGENESIS; LYMPHATIC SYSTEM DISEASE; MOUSE; NONHUMAN; NOONAN SYNDROME; NUCLEAR LOCALIZATION SIGNAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; TISSUE DIFFERENTIATION;

ANIMALS; AORTA; BODY PATTERNING; BUTADIENES; CELLS, CULTURED; ENDOTHELIUM, LYMPHATIC; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; GENE EXPRESSION; GENE EXPRESSION REGULATION, DEVELOPMENTAL; HOMEODOMAIN PROTEINS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; LYMPHANGIECTASIS; LYMPHANGIOGENESIS; MALE; MAP KINASE SIGNALING SYSTEM; MICE; MICE, TRANSGENIC; MUTATION, MISSENSE; NITRILES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-RAF; SOXF TRANSCRIPTION FACTORS; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-3;

EID: 84874631217     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI63034     Document Type: Article

References (45)

1. Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature. 2005;438(7070):946-953. (Pubitemid 43093960)
2. Schulte-Merker S, Sabine A, Petrova TV. Lymphatic vascular morphogenesis in development, physiology, and disease. J Cell Biol. 2011;193(4):607-618.
3. Hosking B, Makinen T. Lymphatic vasculature: a molecular perspective. Bioessays. 2007; 29(12):1192-1202. (Pubitemid 350221788)
4. Wang Y, Oliver G. Current views on the function of the lymphatic vasculature in health and disease. Genes Dev. 2010;24(19):2115-2126.
5. Faul JL, et al. Thoracic lymphangiomas, lymphangiectasis, lymphangiomatosis, and lymphatic dysplasia syndrome. Am J Respir Crit Care Med. 2000;161(3 Pt 1):1037-1046. (Pubitemid 30171769)
6. Adams RH, Alitalo K. Molecular regulation of angiogenesis and lymphangiogenesis. Nat Rev Mol Cell Biol. 2007;8(6):464-478. (Pubitemid 46823443)
7. Aoki Y, Niihori T, Narumi Y, Kure S, Matsubara Y. The RAS/MAPK syndromes: novel roles of the RAS pathway in human genetic disorders. Hum Mutat. 2008;29(8):992-1006.
8. Tidyman WE, Rauen KA. The RASopathies: developmental syndromes of Ras/MAPK pathway dysregulation. Curr Opin Genet Dev. 2009;19(3):230-236.
9. Ren B, et al. ERK1/2-Akt1 crosstalk regulat arteriogenesis in mice and zebrafish. J Clin Invest. 2010;120(4):1217-1228.
10. Kuburovic V, Vukomanovic V, Carcavilla A, Ezquieta- Zubicaray B, Kuburovic N. Two cases of LEOPARD syndrome - RAF1 mutations firstly described in children. Turk J Pediatr. 2011;53(6):687-691.
11. Pandit B, et al. Gain-of-function RAF1 mutations cause Noonan and LEOPARD syndromes with hypertrophic cardiomyopathy. Nat Genet. 2007;39(8):1007-1012. (Pubitemid 47185177)
12. Ko JM, Kim JM, Kim GH, Yoo HW. PTPN11, SOS1, KRAS, and RAF1 gene analysis, and genotype-phenotype correlation in Korean patients with Noonan syndrome. J Hum Genet. 2008;53(11-12):999-1006.
13. Oliver G. Lymphatic vasculature development. Nat Rev Immunol. 2004;4(1):35-45. (Pubitemid 38084130)
14. Srinivasan RS, et al. Lineage tracing demonstrates the venous origin of the mammalian lymphatic vasculature. Genes Dev. 2007;21(19):2422-2432. (Pubitemid 47529372)
15. Wigle JT, Oliver G. Prox1 function is required for the development of the murine lymphatic system. Cell. 1999;98(6):769-778. (Pubitemid 29446894)
16. Francois M, Harvey NL, Hogan BM. The transcriptional control of lymphatic vascular development. Physiology (Bethesda). 2011;26(3):146-155.
17. Francois M, et al. Sox18 induces development of the lymphatic vasculature in mice. Nature. 2008;456(7222):643-647.
18. Hosking B, et al. Sox7 and Sox17 are strain-specific modifiers of the lymphangiogenic defects caused by Sox18 dysfunction in mice. Development. 2009;136(14):2385-2391.
19. Zhang L, et al. VEGFR-3 ligand-binding and kinase activity are required for lymphangiogenesis but not for angiogenesis. Cell Res. 2010;20(12):1319-1331.
20. Makinen T, et al. Isolated lymphatic endothelial cells transduce growth, survival and migratory signals via the VEGF-C/D receptor VEGFR-3. EMBO J. 2001;20(17):4762-4773. (Pubitemid 32848629)
21. Zhou F, et al. Akt/protein kinase B is required for lymphatic network formation, remodeling, and valve development. Am J Pathol. 2010;177(4):2124- 2133.
22. Taniguchi K, et al. Spreds are essential for embryonic lymphangiogenesis by regulating vascular endothelial growth factor receptor 3 signaling. Mol Cell Biol. 2007;27(12):4541-4550. (Pubitemid 46906575)
23. Lapinski PE, et al. RASA1 maintains the lymphatic vasculature in a quiescent functional state in mice. J Clin Invest. 2012;122(2):733-747.
24. Sun JF, et al. Microvascular patterning is controlled by fine-tuning the Akt signal. Proc Natl Acad Sci U S A. 2005;102(1):128-133.
25. von Gise A, et al. YAP1, the nuclear target of Hippo signaling, stimulates heart growth through cardiomyocyte proliferation but not hypertrophy. Proc Natl Acad Sci U S A. 2012;109(7):2394-2399.
26. Razzaque MA, et al. Germline gain-of-function mutations in RAF1 cause Noonan syndrome. Nat Genet. 2007;39(8):1013-1017. (Pubitemid 47185179)
27. Petrova TV, et al. Lymphatic endothelial reprogramming of vascular endothelial cells by the Prox-1 homeobox transcription factor. EMBO J. 2002;21(17):4593-4599. (Pubitemid 34984346)
28. Johnson NC, et al. Lymphatic endothelial cell identity is reversible and its maintenance requires Prox1 activity. Genes Dev. 2008;22(23):3282-3291.
29. Oliver G, Srinivasan RS. Endothelial cell plasticity: how to become and remain a lymphatic endothelial cell. Development. 2010;137(3):363-372.
30. Hong YK, et al. Prox1 is a master control gene in the program specifying lymphatic endothelial cell fate. Dev Dyn. 2002;225(3):351-357.
31. Srinivasan RS, et al. The nuclear hormone receptor Coup-TFII is required for the initiation and early maintenance of Prox1 expression in lymphatic endothelial cells. Genes Dev. 2010;24(7):696-707.
32. Srinivasan RS, Oliver G. Prox1 dosage controls the number of lymphatic endothelial cell progenitors and the formation of the lymphovenous valves. Genes Dev. 2011;25(20):2187-2197.
33. Yang Y, et al. Lymphatic endothelial progenitors bud from the cardinal vein and intersomitic vessels in mammalian embryos. Blood. 2012;120(11):2340- 2348.
34. Wu X, et al. MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation. J Clin Invest. 2011; 121(3):1009-1025.
35. Allanson JE, Roberts AE. Noonan syndrome. In: Pagon RA, Bird TD, Dolan CR, Stephens K, Adam MP, eds. Gene Reviews. Seattle, Washington, USA: University of Washington; 2001.
36. Mouta-Bellum C, et al. Organ-specific lymphangiectasia, arrested lymphatic sprouting, and maturation defects resulting from gene-targeting of the PI3K regulatory isoforms p85alpha, p55alpha, and p50alpha. Dev Dyn. 2009;238(10):2670-2679.
37. Karkkainen MJ, et al. Vascular endothelial growth factor C is required for sprouting of the first lymphatic vessels from embryonic veins. Nat Immunol. 2004;5(1):74-80. (Pubitemid 38081471)
38. Haiko P, et al. Deletion of vascular endothelial growth factor C (VEGF-C) and VEGF-D is not equivalent to VEGF receptor 3 deletion in mouse embryos. Mol Cell Biol. 2008;28(15):4843-4850.
39. Mielgo A, et al. A MEK-independent role for CRAF in mitosis and tumor progression. Nat Med. 2011;17(12):1641-1645.
40. Petrovic I, Kovacevic-Grujicic N, Stevanovic M. Early growth response protein 1 acts as an activator of SOX18 promoter. Exp Mol Med. 2010; 42(2):132-142.
41. Ozturk S, et al. A case of Noonan syndrome with pulmonary and abdominal lymphangiectasia. Int J Clin Pract. 2000;54(4):274-276. (Pubitemid 30319220)
42. Herzog DB, Logan R, Kooistra JB. The Noonan syndrome with intestinal lymphangiectasia. J Pediatr. 1976;88(2):270-272.
43. Kiernan JA. Histological and Histochemical Methods: Theory and Practice. 4th ed. Cold Spring Harbor, New York, USA: Cold Spring Harbor Laboratory Press; 2008.
44. Dull T, et al. A third-generation lentivirus vector with a conditional packaging system. J Virol. 1998;72(11):8463-8471. (Pubitemid 28471781)
45. Luo J, et al. A protocol for rapid generation of recombinant adenoviruses using the AdEasy system. Nat Protoc. 2007;2(5):1236-1247. (Pubitemid 46908240)